MELBOURNE, Australia, March 23 /PRNewswire/ -- Cytopia Limited (ASX: CYT) today announced that it will present data on its JAK2 program at the American Chemical Society Spring meeting, currently underway in Salt Lake City, Utah, USA.
Dr Tracy Nero, Senior Scientist at Cytopia, will be presenting the poster in the Division of Medicinal Chemistry's general poster session on Wednesday, March 25, 2009 from 7:00 PM to 9:00 PM (US ET), Salt Palace Convention Center, Hall 1.
The poster, entitled Small molecule inhibitors of Janus kinases describes preclinical data for a series of JAK2 inhibitors that lead to the identification of CYT387, the company's lead JAK2 drug candidate for the treatment of myeloprofilerative disorders (MPDs). Data for CYT387 in a panel of in vitro assays will be shown, as will comparative data with other described JAK inhibitors.
A separate poster on Cytopia's vascular disrupting agent (VDA), CYT997, has also been presented at the same conference.
The discovery of a specific single activating mutation in the JAK2 enzyme in MPDs in 2005 has focused attention on developing a therapy for these diseases through selective inhibition of JAK2. To successfully address these chronic diseases with a JAK2 inhibitor, the specificity and resultant tolerability profile is a key element of the product profile required for a "best in class" inhibitor.
Cytopia is a world leader in JAK2 kinase chemistry and holds a broad range of JAK2 related patents. The main focus of the JAK2 program is developing orally available JAK2 inhibitors to treat MPDs including myelofibrosis, polycythemia vera and essential thrombocythemia.
CYT387 is a specific JAK2 inhibitor with excellent potential for safe and efficacious chronic human dosing. It has been derived from Cytopia's knowledge of basic biology of JAK kinases, a strong structur
|SOURCE Cytopia Limited|
Copyright©2009 PR Newswire.
All rights reserved